Mylan Inks $30M SEC Deal After Not Disclosing EpiPen Probe
Mylan NV will pay the U.S. Securities and Exchange Commission $30 million to resolve allegations that it failed to warn investors about potential losses tied to an investigation into the drugmaker's...To view the full article, register now.
Already a subscriber? Click here to view full article